A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection

Trial Profile

A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs GEN 003 (Primary) ; Matrix M
  • Indications Herpes simplex virus type 2 infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 15 Sep 2016 Results assessing immune response with Gen-003 published in the Vaccine (2016).
    • 20 May 2015 Results published in the Genocea Biosciences Media Release.
    • 07 May 2015 Results data were presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases in April 2015, according to a Genocea Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top